Nitrofurazone

BLOOD AND BLOOD FORMING ORGANS

Key facts

Nitrofurazone is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1945. DrugCentral lists 3 molecular targets, including Snake venom metalloproteinase Bap1, SARM1 and G6PD. Recorded indications include Enterobacter Cystitis, Enterococcus Urinary Tract Infection, Escherichia coli urinary tract infection and Klebsiella cystitis.

• Approval status: ofm (first approved 1945 by the FDA).
• Molecular targets: Snake venom metalloproteinase Bap1, SARM1 and G6PD (3 listed in DrugCentral).
• Indications: Enterobacter Cystitis, Enterococcus Urinary Tract Infection, Escherichia coli urinary tract infection, Klebsiella cystitis and Staphylococcus Aureus Urinary Tract Infection and others.
• ATC code: B05CA03 (Antiinfectives).
• Molecular formula: C6H6N4O4; molecular weight 198.14 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Enterobacter Cystitis
• Enterococcus Urinary Tract Infection
• Escherichia coli urinary tract infection
• Klebsiella cystitis
• Staphylococcus Aureus Urinary Tract Infection
• Staphylococcus Saprophyticus Urinary Tract Infection

Off-label uses (1)

• Prevention of Bacterial Urinary Tract Infection

Contraindications (18)

• Acute hepatitis
• Anemia due to enzyme deficiency
• Anuria
• Cholestatic hepatitis
• Chronic hepatitis
• Cobalamin deficiency
• Deficiency of glucose-6-phosphate dehydrogenase
• Diabetes mellitus
• Drug-induced hepatitis
• Fibrosis of lung
• Impaired renal function disorder
• Interstitial pneumonia
• Obstructive hyperbilirubinemia
• Oliguria
• Optic neuritis
• Peripheral nerve disease
• Pseudomembranous enterocolitis
• Vitamin B deficiency

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Snake venom metalloproteinase Bap1	—	unknown	IC50 4.06
Sterile alpha and TIR motif-containing protein 1	SARM1	unknown	IC50 4.05
Glucose-6-phosphate 1-dehydrogenase	G6PD	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1945-10-04	FDA	—	SHIRE

ATC classification

ATC code	Therapeutic hierarchy
B05CA03	BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › IRRIGATING SOLUTIONS › Antiinfectives
D08AF01	DERMATOLOGICALS › ANTISEPTICS AND DISINFECTANTS › ANTISEPTICS AND DISINFECTANTS › Nitrofuran derivatives
D09AA03	DERMATOLOGICALS › MEDICATED DRESSINGS › MEDICATED DRESSINGS › Medicated dressings with antiinfectives
P01CC02	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS › Nitrofuran derivatives
S01AX04	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Other antiinfectives
S02AA02	SENSORY ORGANS › OTOLOGICALS › ANTIINFECTIVES › Antiinfectives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Joint dislocation	378.0
Seronegative arthritis	308.4
Joint stiffness	290.9
Prescribed underdose	277.2
Wound infection	244.5
Walking aid user	236.1
Lupus vulgaris	227.7
Retinitis	226.2
Hypercholesterolaemia	217.0
Laryngitis	210.5
Joint range of motion decreased	209.1
Lupus-like syndrome	207.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nitrofurazone is on its molecule page.

• Molecular formula: C₆H₆N₄O₄
• Molecular weight: 198.14 g/mol
• CAS number: 59-87-0
• InChIKey: IAIWVQXQOWNYOU-FPYGCLRLSA-N
• PubChem CID: 5447130

NC(=O)N\N=C\C1=CC=C(O1)[N+]([O-])=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nitrofurazone used for?

DrugCentral lists the following indications for Nitrofurazone: Enterobacter Cystitis, Enterococcus Urinary Tract Infection, Escherichia coli urinary tract infection, Klebsiella cystitis, Staphylococcus Aureus Urinary Tract Infection and Staphylococcus Saprophyticus Urinary Tract Infection.

How does Nitrofurazone work?

Its molecular targets in DrugCentral include Snake venom metalloproteinase Bap1, SARM1 and G6PD.

When was Nitrofurazone first approved?

Nitrofurazone was first approved by the FDA in 1945.

What is the chemical formula of Nitrofurazone?

Nitrofurazone has the molecular formula C6H6N4O4 and a molecular weight of 198.14 g/mol.

Sources

• DrugCentral drug card 1950 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL869 — compound record and bioactivity
• PubChem CID 5447130 — chemical identifiers
• DrugBank DB00336 — drug record
• FDA UNII X8XI70B5Z6 — substance identity
• DailyMed: FDA labels for Nitrofurazone — current prescribing information (label search)
• UniProt Q6SZW1 (SARM1) — target protein
• UniProt P11413 (G6PD) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.